MoonLake Immunotherapeutics (NASDAQ: MLTX)
MoonLake Immunotherapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
MoonLake Immunotherapeutics Company Info
Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.
News & Analysis
These Are Billionaires’ Favorite Healthcare Stocks
The Motley Fool analyzed 16 billionaire-led hedge funds to get an idea of their healthcare sector investment strategies.
Why Shares of MoonLake Immunotherapeutics Are Rising Tuesday
A competitor's clinical trial stumble may be benefiting MoonLake.
Why MoonLake Immunotherapeutics Stock Skyrocketed This Week
Positive mid-stage results fueled a spike in the biotech's shares this week.
Why MoonLake Immunotherapeutics Was Such a Healthy Stock Today
The heavily bullish sentiment on the company only grew on the second trading day of the week.
Why Shares of MoonLake Immunotherapeutics Skyrocketed Monday
The company reported positive phase 2 clinical trial results.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.